Johns Hopkins HIV Guide
Elbasvir/Grazoprevir
INDICATIONS
FDA
FDA
Treatment of hepatitis C infection (HCV) genotypes 1 or 4 in adults with or without ribavirin
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: February 1, 2017
Citation
Smith, Janessa M. "Elbasvir/Grazoprevir." Johns Hopkins HIV Guide, 2017. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545257/all/Elbasvir_Grazoprevir.
Smith JM. Elbasvir/Grazoprevir. Johns Hopkins HIV Guide. 2017. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545257/all/Elbasvir_Grazoprevir. Accessed June 3, 2023.
Smith, J. M. (2017). Elbasvir/Grazoprevir. In Johns Hopkins HIV Guide https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545257/all/Elbasvir_Grazoprevir
Smith JM. Elbasvir/Grazoprevir [Internet]. In: Johns Hopkins HIV Guide. ; 2017. [cited 2023 June 03]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545257/all/Elbasvir_Grazoprevir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Elbasvir/Grazoprevir
ID - 545257
A1 - Smith,Janessa,Pharm.D. BCPS
Y1 - 2017/02/01/
BT - Johns Hopkins HIV Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545257/all/Elbasvir_Grazoprevir
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
